A plain language summary of the 7-year results from the CROWN study: lorlatinib compared with crizotinib in people with ALK-positive non-small cell lung cancer.

Xalkori (crizotinib) - Pfizer

Lorbrena (lorlatinib) - Pfizer

A plain language summary of the 7-year results from the CROWN study: lorlatinib compared with crizotinib in people with ALK-positive non-small cell lung cancer. (PubMed, Future Oncol) - Oct 15, 2026 - No abstract available
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK

http://www.ncbi.nlm.nih.gov/pubmed/42872552

Ali Al-Hashimi; Alice T Shaw; Anna Polli; Benjamin J Solomon; Debra Montague; Dong-Wan Kim; Enriqueta Felip; Francesca Toffalorio; Geoffrey Liu; I-Ming Wang; Jolanda Paolini; Julien Mazieres; Nada Rifi; Nancee Pronsati; Ross A Soo; Todd M Bauer; Tony S K Mok; Yasushi Goto; Yi-Long Wu

Oct 15, 2026